Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Gross Profit for 8 consecutive years, with $177.9 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 20.65% to $177.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $564.0 million through Dec 2025, up 16.77% year-over-year, with the annual reading at $564.0 million for FY2025, 16.77% up from the prior year.
  • Gross Profit for Q4 2025 was $177.9 million at Ultragenyx Pharmaceutical, up from $131.9 million in the prior quarter.
  • The five-year high for Gross Profit was $177.9 million in Q4 2025, with the low at $73.8 million in Q1 2022.
  • Average Gross Profit over 5 years is $105.3 million, with a median of $96.1 million recorded in 2021.
  • The sharpest move saw Gross Profit soared 187.16% in 2021, then decreased 21.62% in 2022.
  • Over 5 years, Gross Profit stood at $79.9 million in 2021, then rose by 22.72% to $98.0 million in 2022, then grew by 17.62% to $115.3 million in 2023, then grew by 27.91% to $147.5 million in 2024, then rose by 20.65% to $177.9 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $177.9 million, $131.9 million, and $143.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.